Skip Navigation

Annals of Oncology 2007 18(11):1757; doi:10.1093/annonc/mdm506
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in Ann Oncol
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

in this issue

In this issue

The first 10% of the full text of this article appears below.


   Prion protein and breast cancer
 
Recently, gene expression profiling and in vitro cell models have shown that ectopic expression of PrPc, a glycosylphosphatidylinositol-anchored protein, expressed by all known mammals, predominantly in the brain, protects mammary tumor cells from cell death induced by TNF. Although PrPc is well known for its implication in transmissible spongiform encephalopathy, evidence has emerged it may function to protect cells from various kinds of internal or environmental stress. In this regard, PrPc over-expression rescues tumor cell lines from pro-apoptotic stimuli and anti-cancer drug treatments. In this . . . [Full Text of this Article]


   DNA repair gene polymorphisms and renal cell carcinoma
 

   Histamine monitoring in patients with CML
 

   Mobile phones for chemotherapy side effects
 

   Quote
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in Ann Oncol:

Efficacy of adjuvant chemotherapy according to Prion protein expression in patients with estrogen receptor-negative breast cancer
F. Meslin, R. Conforti, C. Mazouni, N. Morel, G. Tomasic, F. Drusch, M. Yacoub, J. C. Sabourin, J. Grassi, S. Delaloge, M. C. Mathieu, S. Chouaib, F. Andre, and M. Mehrpour
Ann Oncol 2007 18: 1793-1798. [Abstract] [FREE Full Text]  

The association of DNA repair gene polymorphisms with the development and progression of renal cell carcinoma
S. Sakano, Y. Hinoda, N. Okayama, Y. Kawai, Y. Korenaga, S. Eguchi, K. Nagao, C. Ohmi, and K. Naito
Ann Oncol 2007 18: 1817-1827. [Abstract] [FREE Full Text]  

Clinical and prognostic significance of histamine monitoring in patients with CML during treatment with imatinib (STI571)
H. Agis, W. R. Sperr, S. Herndlhofer, H. Semper, H. Pirc-Danoewinata, O. A. Haas, C. Mannhalter, H. Esterbauer, K. Geissler, C. Sillaber, U. Jäger, and P. Valent
Ann Oncol 2007 18: 1834-1841. [Abstract] [FREE Full Text]  

Application of mobile phone technology for managing chemotherapy-associated side-effects
A. Weaver, A. M. Young, J. Rowntree, N. Townsend, S. Pearson, J. Smith, O. Gibson, W. Cobern, M. Larsen, and L. Tarassenko
Ann Oncol 2007 18: 1887-1892. [Abstract] [FREE Full Text]